The first total synthesis of a saricandin analog corresponding to papulacandin D has been achieved via a highly convergent synthetic strategy. A readily accessible chiral building block 3 was designed and prepared in large scale via an enantioselective reduction with pinanyl-9-BBN. The adaptability of compound 3 toward structural modifications and the highly convergent nature of the approach is illustrated in the construction of the side chain present in saricandin by Pd-catalyzed cross-coupling of 2 and 3 and sequences that include triple bond reduction of fragment C(5-16) and generation of the double bond (C4-C5) using Horner-Emmons reaction. The assembly of the spirocyclic monoglycoside with saricandin side chain is described. A practical technique for isolating the final product 1 after deprotection with TBAF is discussed. Compound 1 was evaluated for its antifungal activity in enzyme assay and cell based assays. However, in contrast the activity reported by Traxler for papulacandin D, the presence of the galactose moiety together with the short fatty acid in natural saricandin seem to be essential for the antifungal activity.
首次实现了与papulacandin D相对应的saricandin类似物的全合成,这一成果是通过高度收敛的合成策略实现的。通过pinanyl-9-BBN的不对称还原,设计并大规模制备了易于获得的手性构建块3。化合物3在结构修饰上的适应性以及方法的高度收敛性,体现在通过
钯催化的交叉偶联反应将2和3构建出saricandin中的侧链,以及包含三键还原片段C(5-16)和使用Horner-Emmons反应生成双键(C4-C5)的序列中。描述了将螺环
单糖苷与saricandin侧链组装的过程。讨论了在用TBAF脱保护后分离最终产物1的实用技术。对化合物1进行了酶活性测试和基于细胞的活性测试,以评估其抗真菌活性。然而,与Traxler报道的papulacandin D活性相比,天然saricandin中存在的半
乳糖部分和短
脂肪酸似乎对抗真菌活性至关重要。